Matinas BioPharma initiates EnACT study of MAT2203 (oral amphotericin B)
Matinas announced it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals. October 14, 2019